

IntelGenx Technologies Corp.  
Form 8-K  
July 22, 2013

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**July 22, 2013**

Date of Report (Date of Earliest Event Reported)

**IntelGenx Technologies Corp.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**

(State or other jurisdiction of  
incorporation)

**000-31187**

(Commission File  
Number)

**870299034**

(IRS Employer Identification  
No.)

**6425 Abrams, Ville St- Laurent, Quebec, Canada H4S 1X9**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 7.01 Regulation FD Disclosure - News Release**

IntelGenx announces submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction

| <u>Exhibit</u> | <u>Description</u> |
|----------------|--------------------|
| 99.1           | Press Release      |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGEX TECHNOLOGIES CORP.**

Dated: July 22, 2013

By: /s/ Horst Zerbe  
Horst G. Zerbe  
President and Chief  
Executive Officer